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Background: Fibrosis or inflammation of the bronchioles is a well-known manifestation of con-
nective tissue disease (CTD). However, the natural history of CTD-related bronchiolitis is
largely unknown.
Methods: We analyzed consecutive patients evaluated at National Jewish Health (Denver, CO)
from 1998 to 2008 with CTD and surgical lung biopsy-confirmed bronchiolitis. Linear mixed ef-
fects models were used to estimate the longitudinal postbronchodilator FEV1 %predicted (%
pred) course and differences between subjects with or without constrictive bronchiolitis (CB).
Results: Of 28 subjects with a mean age of 53  9 years, fourteen (50%) had CB. The most com-
mon CTD diagnosis was rheumatoid arthritis (n Z 14; 50%). There were no significant differ-
ences in demographics, smoking status, underlying CTD diagnoses, 6-min walk distance,
dyspnea score or drug therapy between subjects with CB and those with cellular bronchiolitis.
Three subjects with CB (11%) and four with cellular bronchiolitis (14%) died. Compared with
subjects with CB, those with cellular bronchiolitis had higher mean FEV1 %pred at all times.
There were no significant differences in FEV1 %pred slope within- or between-groups (CB vs.
cellular bronchiolitis) preceding surgical lung biopsy or afterward.
Conclusion: Subjects with CTD-related CB had lower FEV1 %pred values than those with CTD-
related cellular bronchiolitis at all time points, but FEV1 %pred remained stable over time in
both groups regardless of therapy received.
ª 2013 Elsevier Ltd. All rights reserved.ish Health, B’nai B’rith Building, Office #M322, 1400 Jackson Street, Denver, CO 80206, USA. Tel.: þ1
jhealth.org (E.R. Ferna´ndez Pe´rez).
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compatible HRCT (including expiratory images) featuresFibroinflammatory small airways involvement is a clinically
important and frequent lung manifestation of connective
tissue disease (CTD). Immunomodulatory therapies are
often used in attempts to halt the progressive fibrous
luminal narrowing of constrictive bronchiolitis (CB) or the
transmural inflammation of cellular or follicular bronchio-
litis in patients with connective tissue disease- (CTD-)
related bronchiolitis. Pulmonary function tests (PFTs) are
an essential part of standard monitoring in patients with
CTD-related bronchiolitis; however, little is known about
the natural history (or the effects of immunomodulatory
therapy on lung function over time) of bronchiolar disease
in these patients.1e7 Data on longitudinal trends in lung
function is essential for patient management decisions and
for designing therapeutic trials.
The objectives of this study were to examine the longi-
tudinal course of postbronchodilator FEV1 %predicted (%
pred) in a cohort of well-characterized patients with CTD-
related bronchiolitis and to explore whether the course of
FEV1 differed between patients with CB and those with
cellular CTD-related bronchiolitis.Figure 1 a. Constrictive bronchiolitis: bronchovascular
bundle showing complete airway luminal obliteration with
replacement of the bronchiole mucosa by a relatively acellular
scar (arrow). Pentachrome stain 20 magnification. b. Cellular
bronchiolitis: peribronchiolar mononuclear cellular infiltrate
showing concentric luminal narrowing of the airway. Pentach-
rome 40 magnification.Methods
Study design and patients
We searched the National Jewish Health Interstitial
Lung Disease Program Research database and identified
consecutive adult patients with CTD and clin-
icaleradiologicepathologic evidence of bronchiolitis (in the
absence of interstitial lung disease) who were evaluated in
our program between January 1, 1998 and January 1, 2008.
The database of the Interstitial Lung Disease Program at our
institution includes more than 4000 patients who are
registered and followed up prospectively. As part of their
comprehensive evaluation, all patients underwent stan-
dardized clinical evaluation that included serologic testing,
thoracic high-resolution computed tomography (HRCT)
scan, and PFTs. We reviewed the complete medical records
of included subjects and abstracted data pertaining to the
following: demographics, smoking history, CTD diagnosis,
postbronchodilator percent predicted PFTs, 6-min walk,
dyspnea score,8 imaging, histopathology and treatment. A
pulmonologist with expertise in bronchiolar diseases and a
board-certified rheumatologist evaluated every subject.
The National Jewish Health Institutional Review Board
approved this study (protocol HS# 1603). All the patients on
the research database had previously provided informed
consent.
Inclusion criteria
All patients met American College of Rheumatology criteria
for a specific CTD. Diagnostic criteria for bronchiolitis
included the following: (1) presence of compatible clinical
features such as dyspnea, cough, chest tightness, and
wheezing or inspiratory squeaks on auscultation; (2)
abnormal PFT such as an obstructive pattern according tothe guidelines of the American Thoracic Society9; (3)
including one or more of the following findings: cen-
trilobular nodules, tree-in-bud pattern, mosaic attenua-
tion, and air trapping; (4) absence of an alternative
diagnosis that could account for the pathologic or HRCT
findings (e.g., interstitial lung disease such as hypersensi-
tivity pneumonitis, or bronchiolitis obliterans organizing
pneumonia, neuroendocrine cell hyperplasia or infection
based on bacterial, fungal and mycobacterial smears and
cultures); (5) Surgical lung biopsy (SLBx) specimens showing
primarily bronchiolitis. CB was defined histologically by
concentric luminal narrowing of the membranous and res-
piratory bronchioles by submucosal and peribronchiolar
fibrosis without intraluminal granulation tissue or polyps
(Fig. 1(a)).10,11 For the purpose of this study, non-CB was
defined by pathologic patterns of bronchiolitis that were
not CB, including either a chronic lymphoplasmacytic cell
infiltrate in the walls of small airway (cellular bronchiolitis-
Fig. 1(b)) or the presence of hyperplastic lymphoid follicles
with reactive germinal centers distributed along bronchi-
oles (follicular bronchiolitis).10,11
FEV1 in CTD-bronchiolitis 885Thoracoscopic biopsies were performed, with biopsy
sites selected by the surgeon (2). An expert pulmonary
pathologist, blinded to all clinical information, had previ-
ously reviewed all biopsies. On surgical lung biopsy, all
specimens demonstrated concordant histopathologic find-
ings. All patients with a bronchiolitis pattern in SLBx
specimens also had a pattern of bronchiolitis on HRCT.
Statistical analysis
Descriptive statistics were generated for baseline charac-
teristics. Wilcoxon, Student t-tests, chi-square test and
Fisher exact tests were used for univariate comparisons as
appropriate. The date of SLBx was accepted as the date of
diagnosis. Survival period was calculated starting from the
date of diagnosis until death. Vital status was ascertained
on September 30, 2012 via query of the Social Security
Death Index (SSDI). Subjects not appearing in the SSDI were
censored on that date. Given the retrospective design, we
needed to account for the lack of uniformity in the timing
of spirometric assessments among subjects (e.g., some had
spirometry two months after diagnosis, others had them
three months after). Instead of deleting subjects case-wise
because of this heterogeneity in data collection, or using
biased imputation methods, we chose to take advantage of
the benefits of mixed-effects models (SAS Proc Mixed) to
assess spirometric assessments over time. We used this
analytic method to model spirometric assessments as a
function of time before and after SLBx, while adjusting for
age, gender. Time was measured in weeks relative to the
date of SLBx (time 0), and time points of interest were 26
weeks, time 0, þ52, þ104 and þ156 weeks. All statistical
testing was performed at the conventional 2-tailed alpha
level of 0.05. Statistical software packages (JMP, version 9
and SAS version 9.2, SAS Institute Inc., Cary, NC) were used
for data analyses.
Results
Patient characteristics
Of a total of 43 patients identified, 15 were excluded (eight
with primary interstitial lung diseases, two with primary
immunodeficiencies, four did not have a definite CTD
diagnosis and one had chronic mycobacterial infection).
The final cohort consisted of 28 subjects with a mean age of
53  9 years. Fourteen (50%) had CB. All patients had a
HRCT pattern consistent with bronchiolitis and without
opacities suggesting interstitial lung disease. The most
common underlying CTD diagnoses were rheumatoid
arthritis (nZ 14; 50%), primary Sjo¨gren’s syndrome (nZ 7;
25%) and undifferentiated connective tissue disease (nZ 5,
18%). Table 1 displays the clinical characteristics of sub-
jects stratified on the presence or absence of CB. At the
time of diagnosis, there were no significant differences in
demographics, smoking status, underlying CTD diagnosis,
6-min walk distance or therapy between subjects with or
without CB.
Systemic corticosteroids were recommended in all pa-
tients (mean dose 23  14 mg). In patients who did not
respond to corticosteroids according to clinical measures(e.g., symptoms, gas exchange, physiology), cytotoxic
therapy (i.e. azathioprine, mycophenolate mofetil, cyclo-
phosphamide) by means of a standardized treatment and
monitoring protocols was recommended.12 Before SLBx
diagnosis of bronchiolitis in those with rheumatoid arthritis,
four had received methotrexate, three had received
hydroxychloroquine, one had received sulfasalazine and
one was treated with leflunamide. None received gold salts
or d-penicillamine.
Rate of change in FEV1
Compared with patients with CB, those with non-CB had
higher predicted mean FEV1 %pred and FVC %pred at all
times points during the study period (Fig. 2(a) and (b))
especially at 26 weeks before diagnosis, at diagnosis and at
52 weeks (Table 2). There were no significant differences
either within- or between-group estimates for the FEV1 %
pred and FVC %pred change before and after diagnosis
(Table 3). We found no relationship between the course of
FEV1 and the number of FEV1 measurements (data not
shown, p Z 0.69), suggesting that subjects with the
greatest number of observations did not bias model esti-
mates. Spaghetti plots of measured FEV1% and FVC% are
displayed in Fig. 3(a) and (b).
Mortality
Three patients with CB (23%) and four with non-CB (33%)
died during a median follow up of 5.5 years. Male gender
was associated with increased mortality (5 of 7 male pa-
tients, (71%) vs. 2 of 21 female patients, (9%)). Of the seven
deaths, five were due to progressive respiratory failure.
The cause of death was unknown in the remaining patients.
Discussion
To our knowledge, this is the first study to assess the lon-
gitudinal behavior of FEV1 in patients with CTD-related,
SLBx-proven bronchiolitis. We observed that, although
subjects with CB had significantly lower FEV1 values than
subjects with non-CB, the rate of change of FEV1 did not
vary significantly in either subgroup for at least three years
after SLBx.
Our PFT findings in patients CB at study entry are
consistent with that reported in patients with rheumatoid
arthritis-related CB.13 CB is a leading cause of morbidity
and late mortality after lung transplantation.14 Although
non-transplant CB is regarded as a progressive dis-
ease,13,15e17 we did not observe a significant decline in
FEV1 over time in the subgroup with CB. This suggests that,
in patients with CTD-related CB, FEV1 may plateau for
prolonged periods of time, and the natural history of CTD-
related bronchiolitis (CB or non-CB) may progress in a
stair-step pattern.
Our findings challenge the concept that unrelenting,
progressive loss of lung function is inevitable in CB. If
replicated in subsequent studies, this promising news could
influence patient counseling and disease management by
avoiding unnecessary treatment in inherently stable dis-
ease. Similarly, and to our surprise, we did not observe a
Table 1 Baseline characteristic among patients with connective tissue diseases with and without constrictive bronchiolitis.
Characteristics All patients (N Z 28) Histopathologic patternþ P value
CB (n Z 14) Non-CB (n Z 14)
Median follow-up, years 5.5 (3.9e8.2) 5.5 (4.3e7.7) 5.2 (3.5e8.3) 0.67
Mortality rate no. (%) 7 (25) 3 (21) 4 (28) 0.66
Age (years) 53  9 54  6 51  11 0.44
Female sex no. (%) 21 (75) 10 (71) 11 (78) 0.66
Body-mass index 28  6 28  6 27  7 0.40
Smoking status
Previous smoker no. (%) 6 (21) 3 (21) 3 (21) 1.00
Smoking history (pack-year) 22  15 21  16 24  17 0.85
Phenotype no. (%)
Rheumatoid arthritisa 14 (50) 8 (57) 6 (42)
Primary Sjo¨gren’s syndrome 7 (25) 1 (7) 6 (42) 0.11
Undifferentiated connective tissue disease 5 (18) 3 (21) 2 (14)
Otherb 2 (7) 2 (14) 0
Pulmonary function tests, %predictedc
TLC 97  18 94  17 100  19 0.40
RV 181  70 172  64 190  78 0.53
FVC 60  18 55  15 65  20 0.23
FEV1 49  23 43  18 55  27 0.18
FVC/FEV1 ratio 74  20 73  20 76  21 0.79
DLCO 66  18 64  17 69  20 0.49
6-Minute walk
Distance (feet) 1110 (926e1596) 1120 (967e1579) 976 (570e1650) 0.48
Nadir SpO2 91 (89e94) 91 (89e94) 92 (88e93) 0.96
Supplemental O2 flow rate 0.5 (0e3) 0 (0e2) 2 (0e5) 0.26
Heart rate recoveryd 20 (16e23) 17 (15e22) 22 (20e23) 0.16
Dyspnea scoree 9  5 9  7 9  6 0.74
Bronchiolitis medications no. (%)
Prednisone 28 (100) 14 (100) 14 (100) 0.90
Azathioprine 4 (14) 3 (21) 1 (7) 0.27
Mycophenolate mofetil 13 (46) 8 (57) 5 (36) 0.25
Cyclophosphamide 10 (35) 7 (50) 3 (21) 0.07
Macrolide 9 (32) 4 (28) 5 (35) 0.68
Treatment period (months)
Prednisone 13.5 (9e105) 13.5 (9e54) 24 (12e129) 0.41
Azathioprine 14 (3e24) 13.5 (3e24) 14 (13e14) 1.00
Mycophenolate mofetil 19.5 (11.3e57) 36 (12e60) 12 (7e43) 0.29
Cyclophosphamide 11.5 (5.8e15) 12 (6e24) 11 (5e12) 0.49
Macrolide 12 (9.3e20.3) 23 (12e48) 10 (7e12) 0.05
Data are expressed as mean  standard deviation, number (%) or median (25e75% quartiles). CB, constrictive bronchiolitis.
a Two patients with rheumatoid arthritis had secondary Sjo¨gren (one with constrictive bronchiolitis and one with non-constrictive
bronchiolitis).
b Other: scleroderma, microscopic polyangiitis.
c Mean percent of predicted: TLC, total lung capacity; RV, residual volume; FVC, forced vital capacity; FEV1, force expiratory volume
in one second; Dlco, diffusing capacity of the lung for carbon monoxide. No patient had restriction as measured by TLC. Six subjects
(2 constrictive bronchiolitis, 4 non-constrictive bronchiolitis) had an FEV1/FVC ratio 70, elevated RV/TLC ratios and mildly reduced
FEV1at the time of surgical lung biopsy diagnosis.
d Heart rate recovery: defined as the difference between a subject’s heart rate at the 6th minute of the 6-min walk test and at 1 min
after completion of the 6-min walk test.
e ATS dyspnea score: higher score means more deterioration in severity of dyspnea (Reference 7). þ Bronchiolitis pattern on surgical
lung biopsy.
886 E.R. Ferna´ndez Pe´rez et al.significant increase in FEV1 over time in the subgroup with
non-CB. We had expected to see improvements in FEV1 in
this subgroup after treatment.
There was no difference between genders in FEV1
slopes before or after surgical lung biopsy. Nor was
baseline FEV1 associated with changes over time in FEV1(data not shown): the estimated FEV1 values over time in
subjects with lower FEV1 values at baseline (e.g., 50%
predicted or less) remained low over the course of
the study, but the FEV1 slope was no different from
subjects with higher (e.g., >50% predicted) baseline FEV1
values.
Figure 2 a. Mixed-effect model plot of derives estimates for
post-bronchodilator forced expiratory volume in one second
percent predicted over time stratified by the presence or
absence of constrictive bronchiolitis. b. Mixed-effect model
plot of derives estimates for post-bronchodilator forced vital
capacity percent predicted over time stratified by the pres-
ence or absence of constrictive bronchiolitis.
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FEV1 in CTD-bronchiolitis 887An additional important finding of our study is the
impact of gender on survival of CTD-related bronchiolitis. In
our study, male gender was found to be associated with
increased mortality and was the only predictor at diagnosis
in univariate time-to-death analysis (hazard ratio 7.5, 95%
CI 1.6e23.1, p Z 0.01). Another important, practical
observation reflects the finding that subjects with CB had
survival rates similar to subjects with non-CB. The impli-
cation is that airway histology alone does not dictate
prognosis and there are likely multiple factors that do.
Our study has limitations. First, the small sample size
leaves open the possibility that the estimates our models
yielded do not accurately reflect FEV1 course in the greater
population of patients with CTD-related bronchiolitis. How-
ever, because each subject underwent SLBx (study inclusion
criteria) and thorough rheumatological evaluation, we can
be highly confident in the accuracy of the reported airway
and CTD phenotypes. This is a sample with well-defined dis-
ease; and we believe this study is a promising first step in
advancing understanding of CTD-related bronchiolitis. Sec-
ond, subjects had differing amounts of analyzable FEV1 data,
and the timingof assessmentswithin anyone subjectmaynot
Table 3 Age and gender adjusted within- and between-group estimates for postbronchodilator forced expiratory volume in
one second (FEV1) and forced vital capacity change before and after diagnosis (N Z 28).
Change from 26 weeks to
diagnosis
Change from diagnosis to
52 weeks
Change from diagnosis to
104 weeks
Change from diagnosis to
156 weeks
CB Non-CB CB Non-CB CB Non-CB CB Non-CB
FEV1% 2.7  2.8 8.6  3.6 3.5  4.8 4.8  4.9 7.1  9.8 9.6  9.9 8.3  12.5 9.5  12.4
Difference
5.8  4.6 p Z 0.21 1.2  6.9 p Z 0.86 2.5  13.9 p Z 0.85 1.2  17.5 p Z 0.94
FVC% 1.2  2.2 4.9  2.8 4.7  3.7 3.8  3.7 9.4  7.5 7.7  7.5 10.4  8.9 8.7  8.6
Difference
3.7  3.6 p Z 0.31 0.85  5.3 p Z 0.87 1.7  10.7 p Z 0.87 1.8  12.4 p Z 0.88
CB, constrictive bronchiolitis.
Figure 3 a. Spaghetti plot for forced expiratory volume in
one second percent predicted for subjects with and without
constrictive bronchiolitis; each subject represents a single
subject. b. Spaghetti plot for forced vital capacity percent
predicted for subjects with and without constrictive bron-
chiolitis; each subject represents a single subject.
888 E.R. Ferna´ndez Pe´rez et al.have occurred at consistent intervals over time. Mixed-
effects models are perfectly suited for analyzing this type
of data.18 These models accommodate the inherent irregu-
larities (e.g., differences between subjects in the number of
assessments and the inconsistent timing of assessments
within subjects) in retrospective data; they allow formissing
data, thus obviating the need for case-wise deletion; they
handle time-varying covariates andparameterize thewithin-
subject correlation naturally occurring in repeatedmeasures
data. Third, we had no control of when or whether drug
therapy was initiated or what agents were used. In general,
the approach to therapy was similar between sub-
jectsesubjects with more severe airflow limitation were
given a trial of immunomodulatory therapy. Consistent with
this, our analysis of FEV1 over timewith the sample stratified
on whether or not cyclophosphamide (CYC) was used at any
time during the course of disease (data not shown) revealed
that subjects who received CYC had lower FEV1 at all time
points than those who did not receive CYC. There was no
difference in FEV1 slope (either before or after surgical lung
biopsy) between the two groups. Because of the lack of sys-
tematic implementation of therapy, we are unable to confi-
dently make any inferences about the effect of therapy on
the course of FEV1 in patientswith CTD-related bronchiolitis.
Clearly, rationalization and efficacy of treatment cannot be
evaluated without carefully constructed randomized thera-
peutic trials. Finally, the diagnosis and management of CTD-
related bronchiolitis in our subjects was carried out at a
specialized referral center, and our resultsmay not extend to
patients in the community.
In conclusion, in this highly selected, well-characterized
sample of subjects with treated CTD-bronchiolitis, post-
bronchodilator FEV1 values were lower over the course of
the study for the subgroup with CTD-related CB than for the
subgroup with CTD-related non-CB. However, there was no
difference in the FEV1 slope between subgroups. Additional
investigations in larger, but equally well-defined samples
will build on the results of this study and improve under-
standing of CTD-related bronchiolitis.
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